Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/Ritonavir for COVID-19 in Cancer Patients
NCT04455958Phase 2Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lopinavir + ritonavir in coronavirus disease 2019 (COVID-19), sponsored by OHSU Knight Cancer Institute. Planned start May 2021; status: withdrawn.
02
Drugs
lopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04455958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455958.